FIELD: medicine.
SUBSTANCE: present invention refers to biotechnology, more specifically to angiogenesis inhibitors, and can be used in medicine for the pathological angiogenesis inhibition. What is produced is a fusion protein consisting of portion (A) produced of VEGFR outer domain, portion (B) produced of FGFR outer domain, and immunoglobulin Fc-domain (C). The portion (A) produced of VEGFR outer domain consists of second and third lg-like VEGFR2 domains or of first, second and third lg-like VEGFR2 domains. The portion (B) produced of FGFR outer domain consists of (i) a portion produced of an intermediate functional sequence region of the Ig-like FGFR domain, which represents a sequence between the first and second Ig-like domain in FGFR protein, (ii) the second Ig-like FGFR domain and (iii) third Ig-like FGFR domain.
EFFECT: treating the diseases related to disturbed angiogenesis regulation.
21 cl, 6 dwg, 2 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FGF-R-Fc FUSED PROTEIN AND USE THEREOF | 2012 |
|
RU2560573C2 |
| FUSED PROTEINS CONTAINING PDGF AND VEGF BINDING PARTS, AND METHODS FOR USE THEREOF | 2014 |
|
RU2692652C2 |
| EXTRACELLULAR DOMAIN OF TYROSINE KINASE RECEPTOR, ALLOSTERIC BINDING INHIBITOR | 2010 |
|
RU2604805C2 |
| BIFUNCTIONAL ANGIOGENESIS INHIBITOR AND ITS APPLICATION | 2019 |
|
RU2760738C1 |
| HYBRID PROTEINS BASED ON HUMAN Notch3 AS TRAPS-INHIBITORS OF Notch3 SIGNAL TRANSMISSION | 2009 |
|
RU2567662C2 |
| BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
| CHIMERIC PROTEINS, INHIBITING ANGIOGENESIS, AND THEIR APPLICATION | 2005 |
|
RU2355414C2 |
| COMPOSITIONS OF HUMANISED NOTCH FUSED PROTEINS AND METHODS OF TREATING | 2008 |
|
RU2532830C2 |
| ALK1 ANTAGONISTS AND THEIR APPLICATION IN THE TREATMENT OF KIDNEY-CELLULAR CARCINOMA | 2013 |
|
RU2633638C2 |
| INHIBITORS OF RECEPTORS OF TYPE 2 VESSEL ENDOTHELIUM GROWTH FACTOR | 2004 |
|
RU2402567C2 |
